In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) reported that Longboard Capital Advisors, Llc. has picked up 1,312,000 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by Longboard Capital Advisors, Llc. to a total of 1,312,000 representing a 6.58% stake in the company.

For those not familiar with the company, Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

A glance at Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY)’s key stats reveals a current market capitalization of 85.48 Million based on 19.94 Million shares outstanding and a price at last close of $3.85 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-19, Lindstrom picked up 100,000 at a purchase price of $1.79. This brings their total holding to 100,000 as of the date of the filing.

On the sell side, the most recent transaction saw Miloni unload 110,000 shares at a sale price of $8.00. This brings their total holding to 468,576.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.